Two-year treatment outcomes in neovascular age-related macular degeneration with type 3 macular neovascularisation
{{output}}
Background: Neovascular age-related macular degeneration (nAMD) with type 3 macular neovascularisation (MNV) carries a high risk of macular atrophy (MA) during anti-vascular endothelial growth factor (anti-VEGF) treatment. Previo... ...
